Dry Powder Inhalable Vaccines for Shelf Stability and Global Access

Watch this webinar to learn about dry powder formulation and manufacturing for inhaled vaccines, featuring a tuberculosis vaccine candidate from AAHI and Lonza. It covers spray drying for intranasal delivery, critical quality attributes, and aerosol performance, along with the global need for shelf-stable, non-invasive vaccines.

Formulation of Dry Powder Inhaler

Discover how spray drying, a leading particle engineering technique, is revolutionizing pharmaceutical manufacturing, particularly for inhaler formulations. This e-book highlights its advantages in particle control, stability, and potential for complex combination therapies. It also includes expert articles and webinars on improving pulmonary delivery and transforming patient care for rare diseases.

Navigating the Development of Dry Powder for Inhalation: A CDMO Perspective

Interest in pulmonary/nasal drug delivery has grown due to solubility challenges, systemic side effects, and biologics. Newcomers need a CDMO-centric roadmap. This publication, authored by Lonza colleagues, provides a stepwise strategy covering target profiles, formulation choices, particle engineering (jet milling/spray drying), and encapsulation, offering a unified framework for inhaled drug development.

Advancing Dry Powder Inhalers: A Complete Workflow for Carrier‑Based Formulation Development

This peer-reviewed article showcases how our latest jet‑milling research strengthens the way we design and scale inhalation formulations. It highlights how jet‑milling optimization connects directly with formulation design, blending strategies, and scale‑up within a strong QbD framework. It underscores why jet milling is so critical: the study shows how controlling particle‑size distribution and preserving solid‑state integrity directly improves aerosol performance. The article also illustrates the value of an integrated workflow, mirroring the end‑to‑end capabilities we offer across our inhalation programs, from particle engineering through final blend scale‑up.

Dry Powder for Intranasal Delivery

This webinar introduces a non‑invasive approach to delivering biologics through intranasal dry powders. It explains how we’ve overcome the traditional limitations of spray‑drying to create a straightforward, effective formulation strategy that produces optimally sized particles with high yield—suitable for both clinical trials and large‑scale commercial manufacturing. The webinar covers everything from formulation principles and particle engineering to scale‑up considerations and expert techniques for characterizing nasal powders.

Scale-up Considerations for Dry Powder Inhaler Manufacturing by Spray Drying

Spray drying is a versatile particle-engineering tool used to produce respirable dry powders of small molecule APIs and biologics. Production of very small particle sizes (1-5µm) is required for delivery to the deep lung, but also leads to significant challenges in scaling the process from lab-scale dryers to clinical or commercial scale dryers. This webinar addresses the scale-up challenges facing pulmonary dry powders produced by spray drying.